Clinical trials: Depressed
Depressive Disorder
Study Of 323U66 SR In Major Depressive Disorder
This study was designed to evaluate the efficacy and safety in major depressive disorder patients.
- Trial name
- NCT00135512
- Testing
- bupropion hydrochloride
- Where
- 7 sites in Japan
- Volunteers
- 234 people
- Sponsor
- GlaxoSmithKline
Depression, Post-Traumatic Stress Disorder
Improving Quality-of-life and Depressive Symptoms of Combat Veterans Via Internet-based Intervention
Background: Current military involvement in Afghanistan (Operation Enduring Freedom - OEF) and Iraq (Operation Iraqi Freedom - OIF) has created unforeseen burdens on the mental health and well-being of US service women and men.
- Conditions
- Depression, Post-Traumatic Stress Disorder, Functional Status
- Trial name
- NCT01231711
- Testing
- Vets Prevail
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Prevail Health Solutions, LLC
Major Depressive Disorder
Ketamine for Major Depressive Disorder
The purpose of this study is to measure the amount of ketamine in blood over time in subjects diagnosed with Major Depressive Disorder (MDD) and explore the anti-depressive effects of ketamine delivered by transdermal patch.
- Trial name
- NCT03721900
- Testing
- SHX-001 Active low dose, SHX-001 Active High dose
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Shenox Pharmaceuticals, LLC
Bipolar Depression
Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression
The study will evaluate the efficacy and safety of ITI-007 adjunctive to lithium or valproate in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar…
- Trial name
- NCT02600507
- Testing
- Lumateperone (ITI-007)
- Where
- 71 sites in United States, Bulgaria and 3 more
- Volunteers
- 529 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Depression, Major Depressive Disorder
Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements
The purpose of the current study is to perform a unified, homogeneous data collection protocol that includes a large cohort of patients undergoing different treatment options for Major Depressive Disorder (MDD) as an avenue for…
- Trial name
- PREDICT (NCT06002100)
- Testing
- fNIRS measurement
- Where
- 10 sites in United States
- Volunteers
- 540 people
- Sponsor
- Kernel
Depression, Depression, Postpartum
TrueBlue Clinical Study - Investigating the Use of a Mobile Phone App TrueBlue for Monitoring Depression and Anxiety
This trial will assess the safety, feasibility, acceptability, usability and agreement with validated scales of an automated mood monitoring App (TrueBlue), in adult, perinatal participants (recruited between 12 weeks of…
- Conditions
- Depression, Depression, Postpartum, Anxiety in Pregnancy, Anxiety
- Trial name
- NCT06364488
- Testing
- TrueBlue App
- Where
- 2 sites in United Kingdom
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- BlueSkeye AI
Major Depressive Disorder
A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)
This study will evaluate the efficacy, safety and tolerability of agomelatine 25 mg or 50 mg per day and will compare agomelatine and paroxetine tolerability.
- Trial name
- NCT00463242
- Testing
- Agomelatine, paroxetine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 501 people
- Sponsor
- Novartis
Major Depressive Disorder (MDD)
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo.
- Trial name
- Tarian-1 (NCT07300969)
- Testing
- DT-101
- Where
- 43 sites in United States, Bulgaria and 3 more
- Volunteers
- 300 people
- Sponsor
- Draig Therapeutics Ltd
Bipolar I Depression
Lurasidone Pediatric Bipolar Study
A study to evaluate efficacy and safety of flexibly dosed Lurasidone in children and adolescents with bipolar I depression
- Trial name
- Illuminate (NCT02046369)
- Testing
- Lurasidone
- Where
- 66 sites in United States, Bulgaria and 9 more
- Volunteers
- 350 people
- Sponsor
- Sumitomo Pharma America, Inc.
Mental Health Wellness 1, Depression
Examining the Feasibility of a Mobile Mental Health Application in Psychotherapy
There is an urgent need to better understand and manage the mental health burden among working adults. Up to 40% of persons with serious mental illnesses do not receive care or stop intervention programs due to negative stigma.
- Trial name
- NCT04200170
- Testing
- Rose
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Ask Rose
Depressive Episode, Depression
Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)
The objective of this study is to collect data to finalize the development of MEB-001 software as a medical device. The data collected in this study will be used to develop MEB-001 machine learning algorithms by training the…
- Conditions
- Depressive Episode, Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- SAMDE (NCT05708222)
- Testing
- MEB-001
- Where
- 13 sites in United States
- Volunteers
- 715 people
- Sponsor
- Medibio Limited
Depressive Symptoms, Depression
Self-guided Treatment for Adolescents Navigating Depression
The goal of this study is to test whether an investigational mobile app can be a helpful treatment option for adolescents with symptoms of depression.
- Conditions
- Depressive Symptoms, Depression, Depressive Disorder, Depressive Episode
- Trial name
- NCT05462652
- Testing
- Active Intervention
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- Limbix Health, Inc.
Depression
Japanese Phase 1 Multiple Ascending Dose (MAD) Study
The purpose of this clinical study is to assess the safety and tolerability of multiple oral doses of BMS-820836 in healthy Japanese subjects and Japanese patients with depression.
- Trial name
- NCT01396252
- Testing
- BMS-820836
- Where
- Japan
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder
A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication
The objective of the present study is to evaluate whether vortioxetine (10 or 20 mg/day) is at least as effective as agomelatine (25 to 50 mg/day) in patients with depressive symptoms that showed inadequate response to Serotonin…
- Trial name
- REVIVE (NCT01488071)
- Testing
- Vortioxetine (Lu AA21004), Agomelatine
- Volunteers
- 495 people
- Sponsor
- H. Lundbeck A/S
Severe Postpartum Depression
A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in adult female participants diagnosed with severe postpartum…
- Trial name
- NCT02614547
- Testing
- SAGE-547
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Sleep Deprivation, Sleep Hygiene
Breakthrough Anxiety and Sleep Evaluation Using Linked Devices and Smartphone Application Onar (BASEL)
Sleep is not simply the absence of wakefulness. Sleep is an active procedure, normally happening every night, and is absolutely vital. Good sleep is essential for our well-being.
- Conditions
- Sleep Deprivation, Sleep Hygiene, Sleepiness, Sleep Driving
- Trial name
- BASEL (NCT06027047)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Raivotech
Treatment Resistant Depressive Disorder
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
The purpose of this study is to assess the efficacy and dose response of intranasal esketamine (Panel A: 28 mg, 56 mg, and 84 mg and Panel B: 14 mg and 56 mg) compared with placebo in improving depressive symptoms in participants…
- Trial name
- SYNAPSE (NCT01998958)
- Testing
- Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg
- Where
- 25 sites in United States, Belgium and 1 more
- Volunteers
- 108 people
- Sponsor
- Janssen Research & Development, LLC
Postpartum Depression (PPD)
SAINT in Postpartum Depression (PPD)
This study is a large, multi-site clinical trial testing whether Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), a fast-acting form of repetitive transcranial magnetic stimulation (rTMS), can more effectively…
- Trial name
- NCT07210255
- Testing
- SAINT Neuromodulation System
- Where
- 4 sites in United States
- Volunteers
- 192 people
- Sponsor
- Magnus Medical
Major Depressive Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of once daily vortioxetine (Lu AA21004) in adults with major depressive disorder.
- Trial name
- NCT00672958
- Testing
- Vortioxetine
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 600 people
- Sponsor
- Takeda
MDD, Anxiety Disorders
Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)
This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression coexisting with generalized anxiety disorder.
- Trial name
- RECONNECT (NCT04220996)
- Testing
- Vortioxetine
- Where
- 21 sites in Estonia, France and 4 more
- Volunteers
- 100 people
- Sponsor
- H. Lundbeck A/S